Amgen Inc. (AMGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN)

AMGN 317.27

+0.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (1295)	9/27/2006 4:37:44 PM
From: tuck	Read Replies (1) of 1906

Reuters now has an update, and the major change is that AMGN must conduct a post-marketing study to show, well, some kind of survival -- not sure if it's PFS or OS -- in more naive patients. I'd think such a study would help Vectibix' marketing potential anyhow, assuming results are in line with those of the pivotal studies already done. Here's the snip: >>As part of the approval, Amgen committed to conduct a post marketing trial to show whether the drug improves patients' survival in patients with fewer prior chemotherapies, the FDA said.<< Can't find another source for related news yet, just Reuters. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next